MDxHealth S.A.

MDxHealth S.A.

MXDHF

MXDHFMDxHealth S.A. US flag

Other OTC

0.25

USD

-0.02

- -

8.65MMarket Cap

MDxHealth S.A.

MXDHF

(Other OTC)

Recent

price

0.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Stratec SE (SBS.DE)
Optigenex Inc. (OPGX)
H.U. Group Holdings, Inc. (4544.T)
Precision System Science Co., Ltd. (PCNEF)
China Holdings, Inc. (CHHL)
LumiraDx Limited (LMDX)
Business: MDxHealth SA, a commercial-stage precision diagnostics company founded in 2003 and headquartered in Herstal, Belgium, develops and markets molecular diagnostic tests to personalize the diagnosis, prognosis, and treatment of urologic cancers including prostate, bladder, and kidney cancers, as well as other urologic diseases. The company offers a portfolio of proprietary tissue-based and liquid biopsy-based tests utilizing genetic, epigenetic (methylation), exosomal, and other molecular technologies, including ConfirmMDx for post-biopsy prostate cancer detection to address sampling errors; SelectMDx, a urine-based pre-biopsy test to identify men at high or low risk for clinically significant prostate cancer; Genomic Prostate Score (GPS; formerly Oncotype DX Prostate), a tissue-based genomic assay for risk stratification in low- to high-risk localized prostate cancer to guide treatment decisions such as active surveillance; ExoDx Prostate (EPI), a non-invasive urine-based test assessing risk of high-grade prostate cancer with at-home collection option; AssureMDx for bladder cancer detection; ResolveMDx, combining sensitive assay with ASTX for urinary tract infection treatment selection; and InformMDx. MDxHealth operates CLIA-certified laboratories in Irvine, California; Waltham, Massachusetts; Plano, Texas; and Nijmegen, Netherlands, serving physicians, healthcare providers, hospitals, clinics, and laboratories primarily in the United States and Europe. In September 2025, the company closed its acquisition of the Exosome Diagnostics business from Bio-Techne Corporation for $15 million, incorporating the ExoDx Prostate test and related assets to expand liquid biopsy capabilities and accelerate revenue growth to approximately 30% in 2026; earlier acquisitions include the Oncotype DX GPS prostate test from Exact Sciences in 2022. MDxHealth reported preliminary Q2 2025 revenues of $26.6 million (up 20% year-over-year), positive adjusted EBITDA of $1.4 million, and reaffirmed 2025 revenue guidance of $108-110 million, with Q3 2025 revenues reaching $27.4 million (up 18%). The company appointed Michael Holder to its board of directors in July 2025 and continues strategic expansions in precision urology diagnostics.

Company News